{"filings":[{"id":724237,"accession_number":"0001093557-26-000105","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-05-28T21:15:16+00:00","items":["5.07"],"status":"ready","headline":"DexCom announces results of 2026 Annual Meeting, all proposals approved by stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected 12 directors to the board, with each director receiving between 265.9M and 313.6M votes for.","Ratified Deloitte & Touche LLP as independent auditor for FY2026 with 336,046,596 votes for, 373,544 against.","Advisory say-on-pay proposal on executive compensation approved with 277,111,475 votes for and 36,664,959 against.","A quorum of 336,525,352 shares (87.2% of outstanding) was present at the May 27, 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":451843,"accession_number":"0001093557-26-000085","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-05-14T23:31:55+00:00","items":["7.01","8.01"],"status":"ready","headline":"DexCom sets 10%+ annual organic revenue growth target through 2030; authorizes $1B share buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Long-range target: organic revenue growth 10%+ every year through 2030.","2030 non-GAAP gross profit margin target of 67-69%; operating margin 29-30%.","2030 adjusted EBITDA margin target of 36-37%.","Board authorized $1.0B share repurchase program, expiring June 30, 2027.","Prior $250M remaining buyback program terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91241,"accession_number":"0001093557-26-000072","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q1 revenue $1.19B (+15% YoY), EPS $0.51; raises margin guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.192B (+15% YoY); GAAP diluted EPS $0.51, non-GAAP $0.56.","US revenue +11%, international +26% reported (+17% organic) YoY.","GAAP operating margin 21.4% (+850 bps); non-GAAP 22.2% (+840 bps).","FY2026 guidance: revenue $5.16-5.25B; non-GAAP op margin raised to 23-23.5%.","Cash and marketable securities $2.42B; revolver undrawn."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1191900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101209,"accession_number":"0001093557-26-000038","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kevin Sayer returns as DexCom Executive Chairman on Mar 2 with new comp terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Sayer returns from temporary leave effective March 2, 2026, resuming Executive Chairman role.","New letter agreement provides annual base salary of $610,000; no annual bonus.","RSU grant of $2,350,000 to be awarded on March 8, 2026, vesting in full on March 8, 2027.","Former equity awards continue to vest; Sayer no longer eligible for Company's severance plan.","Mark Foletta resumes duties as Lead Independent Director upon Sayer's return."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101208,"accession_number":"0001093557-26-000031","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dexcom appoints Google's Rick Osterloh to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 12 members; Osterloh appointed effective Feb 26, 2026.","Osterloh is SVP, Platforms & Devices at Google, overseeing Android, Chrome, Pixel, Nest, Fitbit.","Initial equity grant of $500,000 in RSUs vesting over three years; annual grant of $101,027 prorated.","Osterloh joins Compensation and Technology Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101207,"accession_number":"0001093557-26-000025","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q4 revenue $1.26B (+13% YoY); GAAP EPS $0.68; FY2026 guidance $5.16-5.25B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP operating income $323M (25.6% margin), up 860bps YoY; Non-GAAP op income $331.5M.","U.S. revenue +11% YoY; international +18% (organic +15%); G7 15-day CGM launched in U.S.","Full year 2025 revenue $4.662B (+16%); GAAP operating margin 19.6%, up 470bps.","FY2026 guidance: revenue $5.16-5.25B (11-13% growth); Non-GAAP op margin ~22-23%.","Cash & marketable securities $2.0B; revolving credit facility undrawn."],"consensus_eps_estimate":null,"consensus_eps_actual":2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":4662000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101206,"accession_number":"0001093557-26-000003","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q4 revenue $1.26B beats high end; FY2026 outlook $5.16-5.25B; new CEO Jake Leach","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue ~$1.260B (+13% YoY), US $892M (+11%), Intl $368M (+18%).","FY2025 revenue ~$4.662B (+16%); reiterates non-GAAP gross margin ~61%, operating margin 20-21%.","FY2026 revenue guidance $5.16-5.25B (+11-13%); non-GAAP gross margin 63-64%, operating margin 22-23%.","Jake Leach assumed CEO role Jan 1, 2026, succeeding Kevin Sayer; presents at JPM conference.","Stelo app reimagined with AI; G7 15 Day system shipping to pharmacies."],"consensus_eps_estimate":null,"consensus_eps_actual":2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":4662000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117550,"accession_number":"0001093557-25-000291","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DexCom appoints Jacob Leach as CEO effective Jan 1, 2026; sets compensation terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacob S. Leach promoted to CEO from President/COO; effective Jan 1, 2026, succeeding Kevin Sayer on medical leave.","Annual base salary $1,150,000; target bonus 150% of base salary.","Granted RSUs valued at $7.5M vesting over 3 years; PSUs target $7.5M based on performance.","Sayer expected to return from medical leave ~March 2026; Foletta remains interim chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117549,"accession_number":"0001093557-25-000278","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q3 revenue $1.209B (+22% YoY); raises FY 2025 revenue guidance to $4.63-4.65B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.70 vs $0.34 YoY; non-GAAP EPS $0.61 vs $0.45 YoY.","U.S. revenue +21% YoY; international revenue +22% reported, +18% organic.","GAAP operating margin 20.1% (480 bps improvement); non-GAAP operating margin 22.6%.","Stelo surpassed $100M revenue in first 12 months; submitted Dexcom Smart Basal to FDA.","Cash and marketable securities $3.32B; revolver undrawn."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":3402400000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117548,"accession_number":"0001093557-25-000264","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dexcom appoints Dr. Euan Ashley to board; board size expanded to 11 in 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Euan Ashley, M.D., to Board effective Oct 24, 2025; board size increased to 10 then to 11 effective Jan 1, 2026.","Ashley chairs Stanford Dept. of Medicine, co-founded 7 biotech firms, brings clinical and AI/digital health expertise.","Received initial RSU grant of $500k vesting over 3 years; eligible for annual director equity grant of $345k.","Appointed to Nominating and Governance Committee and Technology Committee; Kyle Malady steps down from Nominating but remains Tech chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133988,"accession_number":"0001093557-25-000257","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DexCom CEO Kevin Sayer takes temporary medical leave; Jacob Leach appointed interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin R. Sayer, CEO and Chairman, takes temporary medical leave effective Sept 14, 2025.","Jacob S. Leach, President and COO, appointed interim principal executive officer.","Mark Foletta, Lead Independent Director, appointed interim chairman of the Board.","No additional compensation for interim appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133987,"accession_number":"0001093557-25-000241","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Dexcom Q2 revenue $1.157B (+15% YoY); raises FY25 revenue guidance; CEO Sayer to retire, Jake Leach named CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.157B (+15% YoY); GAAP EPS $0.45, non-GAAP EPS $0.48.","Raises FY25 revenue guidance to $4.600-4.625B (14-15% growth); margins reiterated.","CEO Kevin Sayer to retire Jan 1, 2026; becomes Executive Chairman. COO Jake Leach promoted to CEO and Board.","FDA clearance for Dexcom G7 15 Day CGM System received in Q2.","U.S. revenue +15%, international +16% reported (+14% organic)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":2193100000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150731,"accession_number":"0001093557-25-000159","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Dexcom promotes Jake Leach to President and COO; base salary raised to $800K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jake Leach, with 21+ years at Dexcom, promoted to President and COO effective May 9, 2025.","Annual base salary increased to $800,000; target cash bonus at 100% of salary.","As President, Leach adds oversight of corporate development and strategy to existing COO duties.","Leach reports to CEO Kevin Sayer, who remains Chairman and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150730,"accession_number":"0001093557-25-000129","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"DexCom stockholders approve equity plan share increases and elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved 3.4M new shares under Amended & Restated 2015 Equity Incentive Plan.","Stockholders approved 8M new shares under Amended & Restated 2015 Employee Stock Purchase Plan.","Board size reduced to 9 directors effective May 8, 2025.","All nine director nominees elected, including Kevin Sayer and Steven R. Altman.","Ratified Deloitte & Touche as independent auditor for fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150727,"accession_number":"0001093557-25-000134","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K/A","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DexCom assigns director Renée Galá to Audit and Compensation Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Renée Galá appointed to Audit and Compensation Committees effective May 9, 2025.","She joined the DexCom board on March 6, 2025; committee assignments were not previously disclosed.","The amendment updates the initial 8-K filed March 10, 2025, which announced her election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150729,"accession_number":"0001093557-25-000117","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Karen Dahut resigns from DexCom board effective May 8, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karen Dahut resigned from the Board and all committees effective May 8, 2025.","Resignation was not due to any disagreement with management, the Board, or company policies.","No replacement named; board size reduced accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150728,"accession_number":"0001093557-25-000111","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"DexCom Q1 revenue $1.04B (+12% YoY); guides FY25 gross margin ~62% (down); announces $750M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $105.4M ($0.27 diluted EPS) vs $146.4M ($0.36) YoY; non-GAAP EPS $0.32 flat.","Revenue $1.036B (+12% reported, +14% organic); US +15%, intl +7% (organic +12%).","FY25 guidance: revenue $4.6B (+14%), non-GAAP gross margin ~62% (cut from prior), op margin ~21%, EBITDA margin ~30%.","Board authorized $750M share repurchase program through June 30, 2026.","Post-quarter FDA clearance for G7 15-day system; expanded PBM coverage and Stelo on Amazon."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1036000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169665,"accession_number":"0001093557-25-000088","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"DexCom dismisses Ernst & Young, appoints Deloitte as auditor for FY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed EY on March 21, 2025; Deloitte & Touche engaged same day.","No disagreements or reportable events occurred in fiscal years 2024 or 2023.","Deloitte appointed as independent auditor for the fiscal year ending December 31, 2025.","No prior consultations with Deloitte on accounting principles or audit issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169664,"accession_number":"0001093557-25-000050","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"DexCom appoints Renée Galá, Jazz Pharmaceuticals COO, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Renée Galá appointed to DexCom board effective March 6, 2025; term expires at the 2025 annual meeting.","Galá currently serves as President and COO of Jazz Pharmaceuticals, with prior CFO roles at Jazz and Theravance Biopharma.","Received an initial RSU grant with a fair value of $500,000, vesting annually over three years.","Board determined Galá qualifies as an independent director under Nasdaq rules.","Galá also eligible for a pro-rated annual director RSU grant of $56,986 around the 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169663,"accession_number":"0001093557-25-000047","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"DexCom receives FDA warning letter for manufacturing deficiencies; reaffirms FY2025 revenue guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA warning letter cites non-conformities in manufacturing processes and quality systems at San Diego and Mesa facilities.","Inspections occurred Oct–Nov 2024 (San Diego) and June 2024 (Mesa); company had submitted Form 483 responses.","Warning letter does not restrict production, distribution, or 510(k) clearance; no recall required.","DexCom expects no material impact on manufacturing capacity or FY2025 revenue guidance issued Feb 13, 2025.","Company is preparing written response and intends corrective actions; resolution timeline uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169662,"accession_number":"0001093557-25-000029","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q4 revenue $1.114B (+8% YoY); GAAP EPS $0.38; FY2025 guidance $4.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.114B (+8% YoY); U.S. +4%, international +17% reported.","GAAP net income $151.7M ($0.38 diluted EPS) vs $256.3M ($0.62) YoY; non-GAAP EPS $0.45 vs $0.50.","Full year 2024 revenue $4.033B (+11% YoY); GAAP operating margin 14.9% (-160bps); non-GAAP margin 18.8% (-100bps).","Submitted G7 15-day CGM to FDA; secured Dexcom ONE+ reimbursement in France; partnership with ŌURA.","FY2025 guidance: revenue $4.60B (+14% growth); non-GAAP gross margin ~64-65%; operating margin ~21%; Adj. EBITDA ~30%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":4033000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169661,"accession_number":"0001093557-25-000004","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom reports preliminary Q4 revenue $1.113B (+8% YoY); guides 2025 revenue $4.60B (+14%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 preliminary revenue at least $1.113B, up 8% YoY; US revenue $803M (+4%), international $310M (+17%).","FY2024 total preliminary revenue ~$4.032B, up 11% YoY.","Updated 2024 non-GAAP gross margin guidance to 62% and operating margin to 19%; Q4 margin hit by non-cash charge.","2025 revenue guidance $4.60B (+14%); non-GAAP gross margin 64-65%, operating margin ~21%."],"consensus_eps_estimate":null,"consensus_eps_actual":1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":4033000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186720,"accession_number":"0001093557-24-000197","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"DexCom and Abbott settle global patent litigation, enter royalty-free cross-license","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["DexCom and Abbott signed a settlement and patent cross-license agreement on Dec 20, 2024.","Each party grants the other a worldwide, royalty-free, non-exclusive license to certain analyte-sensing patents.","No royalties or any financial compensation are required under the agreement.","Both parties entered a covenant not to sue until December 20, 2034.","Non-challenge provisions apply to licensed patents for varying periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186719,"accession_number":"0001093557-24-000179","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q3 revenue $994M (+2%); reiterates FY24 guidance; CCO retiring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $994.2M (+2% reported, +3% organic); U.S. down 2%, international up 12%.","GAAP net income $134.6M ($0.34 EPS); Non-GAAP $179.9M ($0.45 EPS). Operating margin contracted.","Launched Stelo OTC glucose biosensor in U.S.; Dexcom G7 in Australia, ONE+ in France.","FY24 guidance reaffirmed: revenue ~$4.00-4.05B, non-GAAP operating margin ~20%.","Teri Lawver, EVP & Chief Commercial Officer, retiring year-end; CEO Sayer leading commercial while search ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2919500000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203282,"accession_number":"0001093557-24-000143","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Dexcom Q2 rev $1.004B (+15%); GAAP EPS $0.35; lowers FY rev guidance to $4.00-4.05B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.004B (+15% YoY); US +19%, intl +7% reported; organic growth 16%.","GAAP EPS $0.35, Non-GAAP EPS $0.43; GAAP operating income $158.0M (15.7% margin).","FY2024 revenue guidance lowered to ~$4.00-4.05B (11-13% organic); Q3 rev guidance $975M-$1.00B.","Announces $750M share repurchase program authorized through June 30, 2025.","CEO Kevin Sayer acknowledges execution shortfall but cites long-term growth opportunity."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1925300000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219636,"accession_number":"0001093557-24-000101","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DexCom annual meeting results: directors elected, EY ratified, say-on-pay approved, two shareholder proposals decided","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all 10 director nominees; Kevin R. Sayer received 319.8M votes for, 19.8M against.","Ratified Ernst & Young as independent auditor for FY2024 with 329.3M votes for, 23.4M against.","Advisory vote on named executive officer compensation approved with 307.9M for, 33.4M against.","Stockholder proposal on pay equity disclosure failed (118.6M for, 211.8M against).","Stockholder proposal on transparency in lobbying passed (176.1M for, 163.3M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219635,"accession_number":"0001093557-24-000078","cik":1093557,"company_name":"DEXCOM INC","ticker":"DXCM","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dexcom Q1 revenue up 24% to $921M; GAAP EPS $0.36; updates FY guidance to $4.2-4.35B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $921M (+24% YoY); GAAP net income $146.4M ($0.36 EPS) vs $48.6M ($0.12) in Q1 2023.","Non-GAAP operating margin 15.2% (up 460 bps YoY); Non-GAAP EPS $0.32.","FDA cleared Stelo, first OTC CGM for type 2 diabetes not on insulin; also cleared Direct-to-Watch for G7.","Updated FY2024 revenue guidance to $4.20-4.35B (17-21% organic growth); reiterated Non-GAAP gross margin ~63-64% and operating margin ~20%.","Cash $2.9B; revolving credit facility undrawn."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":921000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":27111434645.155117,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}